Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seagen Inc (NQ: SGEN )

139.00 -0.64 (-0.46%)
Streaming Delayed Price Updated: 11:09 AM EDT, May 23, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 143,611
Open 141.92
Bid (Size) 138.90 (2)
Ask (Size) 139.06 (2)
Prev. Close 139.64
Today's Range 138.67 - 142.07
52wk Range 105.43 - 192.79
Shares Outstanding 181,934,500
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Seagen Posts Encouraging Data From Tucatinib Combo Trial In Colorectal Cancer
 
Via Benzinga
Seagen Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA® (tucatinib) in Combination With Trastuzumab in HER2-Positive Metastatic Colorectal Cancer
From Seagen Inc.
Via Business Wire

Performance

YTD
-11.94%
-11.94%
1 Month
+0.72%
+0.72%
3 Month
+12.61%
+12.61%
6 Month
-21.08%
-21.08%
1 Year
-9.55%
-9.55%

More News

Read More
Seagen CEO Clay Siegall Resigns After Domestic Violence Arrest
Via Investor's Business Daily
Seagen Announces Resignation of President, Chairman & CEO Clay Siegall
From Seagen Inc.
Via Business Wire
Amid Domestic Violence Allegation, Longtime Seagen CEO Takes Leave of Absence
Via Benzinga
Seagen CEO Clay Siegall Placed On Leave After Domestic Violence Claim
Via Investor's Business Daily
Expert Ratings for Seagen
Via Benzinga
Large Cap Biopharmaceuticals: Provide Growth, Value And Yield
Via Talk Markets
77 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
103 Biggest Movers From Yesterday
Via Benzinga
Seagen President, CEO and Chairman Clay Siegall Takes Leave of Absence
From Seagen Inc.
Via Business Wire
Looking Into Seattle Genetics's Return On Capital Employed
Via Benzinga
4 Healthcare Funds With "Double Discounts"
Via Talk Markets
Read Why This Analyst Is 'Encouraged' By Seagen's Q1 Sales
Via Benzinga
Recap: Seagen Q1 Earnings
Via Benzinga
Seagen Reports First Quarter 2022 Financial Results
From Seagen Inc.
Via Business Wire
Seagen to Highlight Data from Expanding Oncology Portfolio at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
From Seagen Inc.
Via Business Wire
Seagen Announces Plans to Expand Pacific Northwest Biomanufacturing Capacity to Support Growing Portfolio of Transformative Cancer Medicines
From Seagen Inc.
Via Business Wire
Earnings Scheduled For April 28, 2022
Via Benzinga
Astellas - Seagen's Padcev Approved In Europe For Most Common Form Of Bladder Cancer
Via Benzinga
European Commission Approves PADCEV™ (enfortumab vedotin) for Locally Advanced or Metastatic Urothelial Cancer
From Seagen Inc.
Via Business Wire
Seagen Wins $42M Patent Claim Against Daiichi In Cancer Drug Case
Via Benzinga
Seagen Announces Jury Award in Patent Infringement Case Against Daiichi Sankyo
From Seagen Inc.
Via Business Wire
Seagen to Highlight Preclinical Data for Enfortumab Vedotin and Two Novel Antibody-Drug Conjugates at AACR Annual Meeting
From Seagen Inc.
Via Business Wire
Seagen to Host Conference Call and Webcast Discussion of First Quarter 2022 Financial Results on April 28, 2022
From Seagen Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.